openPR Logo
Press release

Deadline on May 11th coming up in Lawsuit for Investors in Allakos Inc. (NASDAQ: ALLK)

04-27-2020 07:30 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on May 11, 2020 in the lawsuit for certain investors in Allakos Inc. (NASDAQ: ALLK).

A Deadline is coming up on May 11, 2020 in the lawsuit for certain investors in Allakos Inc. (NASDAQ: ALLK).

A deadline is coming up on May 11, 2020 in the lawsuit filed for certain investors of Allakos Inc. (NASDAQ: ALLK) over alleged securities laws violations by Allakos Inc. (NASDAQ: ALLK).

Investors who purchased shares of Allakos Inc. (NASDAQ: ALLK) have certain options and there are strict and short deadlines running. Deadline: May 11, 2020. NASDAQ: ALLK stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Allakos Inc. (NASDAQ: ALLK) common shares between August 5, 2019 and December 17, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 5, 2019 and December 17, 2019, the defendants made false and/or misleading statements and/or failed to disclose that: The Company's ENIGMA Trial for its flagship drug, AK002, was poorly designed, that Allakos cherrypicked timeframes and to engineer results for the ENIGMA trial, that Allakos used superficial endpoints in the ENIGMA Trial relative to FDA guidance, that Allakos misrepresented the number of adverse incidents that occurred during the ENIGMA Trial, that the ENIGMA Trial was not well-controlled, that Allakos failed to report key data from the ENIGMA Trial, and that as a result, defendants' statements about Allakos' business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Those who purchased shares of Allakos Inc. (NASDAQ: ALLK) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on May 11th coming up in Lawsuit for Investors in Allakos Inc. (NASDAQ: ALLK) here

News-ID: 2026402 • Views:

More Releases from Shareholders Foundation

Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, 2025
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd. Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm

All 5 Releases


More Releases for Allakos

Vernal keratoconjunctivitis Pipeline Analysis & Clinical Trials, 2025, DelveInsi …
DelveInsight's, "Vernal Keratoconjunctivitis - Pipeline Insight, 2025," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. DelveInsight reports that over 5 key companies are actively engaged
Investigation announced for Investors in shares of Allakos Inc. (NASDAQ: ALLK) o …
An investigation on behalf of current long-term investors in shares of Allakos Inc. (NASDAQ: ALLK) was announced over potential breaches of fiduciary duties by certain officers and directors at Allakos Inc. Investors who purchased shares of Allakos Inc. (NASDAQ: ALLK) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Allakos Inc. directors breached their fiduciary
Allergic Conjunctivitis - Drug Pipeline Landscape, 2023 | Aldeyra Therapeutics, …
Allergic conjunctivitis is inflammation of the conjunctiva caused by an allergic reaction. Allergic conjunctivitis is caused by allergens and irritants, such as pollen, dust and mold. Allergic conjunctivitis can be grouped into two types seasonal allergic conjunctivitis and perennial allergic conjunctivitis. To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31211 Symptoms of allergic conjunctivitis include red or pink eyes, pain, itchiness, swollen eyelids and soreness. Diagnostic tests of allergic conjunctivitis
Atopic Dermatitis - Drug Pipeline Landscape, 2022 | Allakos, Inc, Amgen, Amtixbi …
Atopic dermatitis (eczema) is a condition that causes dry, itchy and inflamed skin. It's characterized by inflamed skin that may and release a clear fluid when scratched. Eczema damages the skin barrier function that makes skin more sensitive and more prone to infection and dryness. Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers and stress. A weak skin barrier function might also trigger an immune
Vernal Keratoconjunctivitis Market Competitive Insights 2021 - 2026 | Allakos, …
The report provides an overview of the many approaches employed to retain their place in the Vernal Keratoconjunctivitis market by industry participants. In combination for use in geometric surveying, SWOT analysis, statistical analyses, PESTLE analysis, and real-time testing approaches are utilized. It comprises a study of major participants in the industry and their latest market policies to enable new market participants, stakeholders, and shareholders to build successful company plans. Ask For
Investigation announced for Long-Term Investors in Allakos Inc. (NASDAQ: ALLK)
An investigation was announced. for long-term investors in shares of Allakos Inc. (NASDAQ: ALLK) concerning potential breaches of fiduciary duties by certain directors and officers of Allakos Inc. Investors who are current long term investors in Allakos Inc. (NASDAQ: ALLK) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: